Transgene (Euronext Paris:TNG), located in Strasbourg, France, has entered into a license agreement with NEC Bio B.V., a subsidiary of NEC Corporation, for the clinical development of TG4050, an individualized cancer vaccine targeting HPV-negative head and neck cancer. This innovative therapy utilizes a modified vaccinia virus (MVA) vector that incorporates neoantigens selected through NEC's AI-enabled prediction platform. The partnership aims to enhance treatment efficacy and prevent cancer relapse following surgery and adjuvant therapy. Under the agreement, Transgene will gain access to NEC’s AI-based neoantigen prediction technology, which is crucial for the further development of TG4050. NEC will receive a technology access fee of €2.5 million in shares and an additional €2.5 million in cash, along with potential milestone payments and a share of profits. Transgene plans to issue 3,345,824 new shares to NEC at a price of €0.7472 per share, which will represent 1.22% of its capital post-issuance. The capital increase is expected to be completed by the end of April 2026. Currently, TG4050 is in Phase 2 trials, utilizing NEC’s Neoantigen Prediction System, which employs machine learning to identify mutations that can provoke robust immune responses.